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Introductory Article
Guidelines for the Management of
Degenerative Cervical Myelopathy and
Acute Spinal Cord Injury: Development
Process and Methodology
Lindsay A. Tetreault, PhD1,2,*, Andrea C. Skelly, PhD3,*,
Joseph R. Dettori, PhD, MPH3, Jefferson R. Wilson, MD, PhD4,
Allan R. Martin, MD1, and Michael G. Fehlings, MD, PhD, FRCSC, FACS1,4
Abstract
The Institute of Medicine defines clinical practice guidelines as “statements that include recommendations intended to optimize
patient care that are informed by a systematic review of evidence and an assessment of the benefits and harms of alternative care
options.” Guidelines help clinicians implement best evidence into practice and encourage informed shared decision making with
patients. Guidelines are intended to enhance the quality of patient care by discouraging ineffective and potentially harmful
interventions and standardizing practice. Standards for the development and appraisal of guidelines, such as those proposed by the
Institute of Medicine and other organizations, help assure guideline quality and credibility. Primary standards include establishing
transparency, managing conflicts of interest, forming a multidisciplinary guideline development group, conducting methodologi-
cally sound systematic reviews, developing evidence-based recommendations, balancing risks and harms, and rating the strength
of recommendations based on the confidence in the evidence. Furthermore, the guideline document must be appraised internally
and externally and updated when new evidence arises. The Grading of Recommendation, Assessment, Development and Eva-
luation process helps appraise the existing body of evidence as well as provide an interactive framework for weighing the benefits
and harms of treatment options and translating evidence to recommendations. This article summarizes the methodology used to
develop clinical practice guidelines for the management of degenerative cervical myelopathy and acute spinal cord injury.
Keywords
spinal cord injury, guidelines, methodology, guideline development, degenerative cervical myelopathy, cervical spondylotic
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Introduction
The Institute of Medicine (IOM) defines clinical practice
guidelines as “statements that include recommendations
intended to optimize patient care that are informed by a sys-
tematic review of evidence and an assessment of the benefits
and harms of alternative care options.”1 Guidelines (1) are a
way of implementing evidence into practice; (2) focus on
improving quality of care; (3) reduce health care variations,
improve diagnostic accuracy, promote effective therapies,
and discourage ineffective and potentially harmful interven-
tions; (4) represent the best judgement of a team of experi-
enced clinicians and methodologists; (5) can potentially form
the basis for measuring performance; and (6) can be imple-
mented into practice if well designed. In contrast, guidelines
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are not intended to be the sole source for treatment decisions,
supersede professional judgement, or be used for reimburse-
ment policies, performance measures, legal precedents, com-
prehensive management, or as measures of certification or
licensing.2
Well-conducted clinical practice guidelines can substan-
tially improve patient care as well as treatment outcomes by
standardizing management strategies, and encouraging clini-
cians to make evidence-informed decisions. The methodology
used for their development, however, must be rigorous. In the
past 2 decades, substantial variation in the quality of clinical
practice guidelines prompted the implementation of standards
and more rigorous processes for guideline development.3-7
Such standards have helped improve the credibility of guide-
lines, are required for publication in the Agency for Health-
care Research and Quality’s National Guideline
Clearinghouse,8 and are increasingly used by policy makers
to assess guideline quality.
There is substantial overlap between standards published by
the IOM1 and the Guidelines International Network6 for the
development and reporting of high-quality and trustworthy
guidelines. Primary tenets include the following:
 Establish transparency by disclosing funding sources,
achieving editorial independence, and following a
protocol.
 Manage conflict of interests, including intellectual and
financial conflicts.
 Create a multidisciplinary guideline development group
(GDG) that includes a patient or patient advocate.
 Conduct methodologically sound systematic reviews
that appraise the evidence and contain an appropriate
balance between systematic review and guideline devel-
opment teams.
 Create clear and actionable recommendations that expli-
citly link critically appraised and synthesized evidence
to rationale of recommendations.
 Balance risks and harms.
 Rate the strength of recommendations based on confi-
dence in the evidence and effect sizes.
 External review by a multidisciplinary group.
 Update as new evidence becomes available and as prac-
tice changes.
The Grading of Recommendation, Assessment, Develop-
ment and Evaluation (GRADE) process is the most widely used
method for assessing the overall quality (strength) of evidence
for a specific outcome. The quality of evidence is described as
high, moderate, low, or very low, based on the confidence that
the observed effect sizes reflect the true effect.9,10 The GRADE
process for guideline development implements standards and
provides a step-wise process that considers the following fac-
tors: the overall certainty and quality of evidence with respect
to both benefits and harms; the value and importance of spe-
cific outcomes to various stakeholders, including patients, clin-
icians, and payers; the relative effect sizes of anticipated
desirable and undesirable effects; resource use and cost-
effectiveness; impact on health inequities; applicability; and
feasibility. Recommendations are then formed based on
these considerations as well as a formal balance of the
desirable and undesirable consequences; the overall confi-
dence in the evidence ultimately determines the strength of
the recommendation. The GRADE framework also provides
a process for articulating the evidence, judgements, and
rationale (including the role of expert opinion) used to sup-
port the recommendation, and for identifying gaps in the
evidence.10 This article summarizes the methodology used
to develop a clinical practice guideline for the management
of degenerative cervical myelopathy (DCM) and acute
spinal cord injury (SCI).
Methods for Guideline Development
Overview of the Process
There are critical knowledge gaps and variability in the care
of patients with DCM and acute SCI. Following a series of
meetings and webinars, the leadership group agreed there
was a need to develop clinical practice guidelines to address
key questions and resolve existing controversy surrounding
the management of DCM and acute SCI. Multidisciplinary
systematic review teams and a GDG were formed based on
input from the leadership group and were required to dis-
close potential conflicts of interest. These disclosures were
self-reported by members of the group; there may be some
inherent conflicts of interest as all participants were expe-
rienced in the treatment of patients with DCM and/or acute
SCI (see the appendix). There was some overlap between
groups. Expert methodologists, with no important financial
or intellectual conflicts of interest, conducted several sys-
tematic reviews to synthesize the evidence required to for-
mulate recommendations. These methodologists were
experienced in the application of GRADE and also directed
the guideline development process. The Conference on
Guideline Standardization (COGS) Checklist for Reporting
Clinical Practice Guidelines,7 with reference to IOM Stan-
dards,1 was used to establish transparency, apply develop-
ment standards, and refine the scope and intention of the
guidelines. GRADE methods were used to assess the overall
quality of evidence and document GDG discussions that
guided the formation of the recommendations.10 In-person
meetings and webinars were used throughout the process.
The guidelines were internally and externally appraised;
results of these reviews, a summary of the final voting, as
well as any substantial changes to the guidelines were
documented.
Developer
DCM Guidelines. The guideline for the management of DCM
was developed under the auspices of AOSpine North America
(AOSNA) and the Cervical Spine Research Society (CSRS).
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AOSNA is an academic spine surgeon professional society
and 1 of the 5 global regions of AOSpine International, a
Clinical Division of the AO Foundation based in Davos, Swit-
zerland. AOSpine is a “leading global academic community
for innovative education and research in spine care, inspiring
lifelong learning and improving patients’ lives.” Furthermore,
it is “an international community of spine surgeons generat-
ing, distributing, and exchanging knowledge to advance sci-
ence and the spine care profession through research,
education, and community development. With this collabora-
tive approach, AOSpine continues to advance spine care
worldwide.” The CSRS is an organization of spine care pro-
fessionals interested in clinical and research problems related
to the cervical spine.
SCI Guidelines. The guideline for the management of acute SCI
was sponsored by AOSpine North America, AOSpine Inter-
national, and the Section on Neurotrauma and Critical Care of
the American Association and Congress of Neurological Sur-
geons. The American Association of Neurological Surgeons
(AANS) is a scientific and educational association that
focuses on advancing the specialty of neurological surgery.
There are approximately 10 500 members worldwide. They
have a joint section with the Congress of Neurological Sur-
geons (CNS; total membership, 9100); together the AANS
and CNS aim to define the use of spinal neurosurgical meth-
ods for the treatment of diseases of the spinal neural elements,
the spine, and peripheral nerves. Their overall objectives
include to advance spinal neurosurgery and related sciences,
improve patient care, support meaningful basic and clinical
research, and provide leadership in undergraduate and grad-
uate education.
Composition of Guideline Development Group
DCM Guidelines. Our multidisciplinary GDG consisted of 17
spine surgeons (neurosurgeons, orthopedic surgeons),
2 neurologists, 1 rheumatologist, 3 physical medicine/
rehabilitation specialists, 2 primary care physicians, 1
nurse, and 1 clinical researcher (Table 1). The GDG did
not include a patient representative or a member from the
public.
SCI Guidelines. Our multidisciplinary GDG consisted of 20 spine
surgeons (neurosurgeons, orthopedic surgeons), 1 neurologist,
4 physical medicine/rehabilitation specialists, 1 vascular med-
icine specialist, 1 anesthesiologist, 2 patient advocates, 1 nurse,
and 1 clinical researcher (Table 2).
For both guidelines projects, the GDG had full editorial
independence from the sponsors and included stakeholders
who were not members of these organizations. Two metho-
dologists from Spectrum Research, Inc, experienced in the
accepted methodology for systematic reviews and guideline
development, served as nonvoting participants and coordi-
nated the process as a neutral party. Members of the GDG
were required to complete a disclosure form detailing
financial, personal, and intellectual conflicts of interests
(summarized in the appendix) and verbally indicate relevant
conflicts prior to each meeting. Before voting, individuals
with relevant conflicts of interest were asked to recuse them-
selves from voting. Advice on conflict of interest manage-
ment was provided by the methodologists at a number of
stages throughout the development process. The leadership
teams, however, were ultimately responsible for managing
relevant conflicts.
Table 1. Participants of the Guideline Development Group for
Degenerative Cervical Myelopathy.
Name Specialty
Guideline Development Leadership Committee Members
Michael G. Fehlings, Co-Chair Neurosurgery
Jeffrey C. Wang, Co-Chair Orthopedic Surgery
Lindsay A. Tetreault, Vice Chair and
Systematic Review Coordinator
Research
K. Daniel Riew, General Member of the
Leadership
Orthopedic Surgery
James W. Middleton, General Member
of the Leadership
Physical/Rehabilitation
Medicine
Guideline Development Group
Bizhan Aarabi Neurosurgery
Paul M. Arnold Neurosurgery
Darrel S. Brodke Orthopedic Surgery
Anthony S. Burns Physical/Rehabilitation
Medicine
Simon Carette Rheumatology
Robert Chen Neurology
Kazuhiro Chiba Orthopedic Surgery
Julio C. Furlan Neurology
James S. Harrop Neurosurgery
Langston Holly Neurosurgery
Sukhvinder Kalsi-Ryan Physical/Rehabilitation
Medicine
Mark Kotter Neurosurgery
Brian K. Kwon Orthopedic Surgery
Allan R. Martin Neurosurgery
James Milligan Primary Care
Hiroaki Nakashima Orthopedic Surgery
Narihito Nagoshi Orthopedic Surgery
John Rhee Orthopedic Surgery
Anoushka Singh Nursing
Sumeet Sodhi Primary Care
Jefferson R. Wilson Neurosurgery
Albert Yee Orthopedic Surgery
Methodologists (non-voting)
Andrea C. Skelly, PhD, MPH Epidemiologist, Systematic
Review Methodologist
Joseph R. Dettori, PhD, MPH Epidemiologist, Systematic
Review Methodologist
Non-voting Observers or Administrators
Chris Ahuja Neurosurgery
Nancy Holmes AOSpine North America
Chi Lam AOSpine North America
Kelly McCormick AOSpine North America
Anick Nater Neurosurgery
Aria Nouri Research
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Systematic Review of the Evidence
Systematic reviews were performed to summarize and synthe-
size the evidence required for the DCM and SCI guidelines.
These reviews are published separately in this focus issue. The
primary clinical questions addressed in these systematic
reviews are summarized in Tables 3 and 4.
Spectrum Research, Inc, an independent evidence-based
practice center, provided the methodological expertise
needed to perform these systematic reviews. Reviews were
conducted according to accepted methodological stan-
dards8,11,12 (eg, Institute of Medicine, Agency for Health-
care Research and Quality, and Patient-Centered Outcomes
Research Institute) and used similar methods as previously
published systematic reviews.13 Spectrum methodologists
worked with clinical experts to ensure that the results were
accurate and clinically appropriate. Specifically, the metho-
dologists were responsible for conducting the systematic
search, determining the inclusion/exclusion of retrieved arti-
cles, synthesizing results, and grading the evidence. Clinical
authors were primarily responsible for developing the key
questions and writing the introduction and discussion sec-
tions of these reviews.
Systematic review teams were selected by the leadership
groups and included members from the GDG as well as clin-
icians that were not part of the GDG. Detailed methods are
described in each individual review, including search strate-
gies, search dates, inclusion/exclusion criteria (set a priori),
Table 2. Participants of the Guideline Development Group for Acute
Spinal Cord Injury.
Name Specialty
Guideline Development Leadership Committee Members
Michael G. Fehlings, Co-Chair Neurosurgery
James Harrop, Co-Chair Neurosurgery
Jefferson R. Wilson, Vice Chair Neurosurgery
Anthony Burns, Vice Chair Physical/Rehabilitations Medicine
Brian Kwon, General Member
of the Leadership
Orthopedic Surgery
Lindsay Tetreault, Systematic
Review Coordinator
Research
Guideline Development Group
Bizhan Aarabi Neurosurgery
Paul Anderson Orthopedic Surgery
Paul M. Arnold Neurosurgery
Darrel Brodke Orthopedic Surgery
Kazuhiro Chiba Orthopedic Surgery
Julio C. Furlan Neurology
Gregory Hawryluk Neurosurgery
Langston Holly Neurosurgery
Susan Howley Patient Advocate, Christopher and
Dana Reeve Foundation
Tara Jeji Patient Advocate, Ontario
Neurotrauma Foundation
Sukhvinder Kalsi-Ryan Physical/Rehabilitation Medicine
Mark Kotter Neurosurgery
Shekar Kurpad Neurosurgery
Ralph Marino Physical/Rehabilitation Medicine
Allan R. Martin Neurosurgery
Eric Massicotte Neurosurgery
Geno Merli Vascular Medicine
James Middleton Physical/Rehabilitation Medicine
Hiroaki Nakashima Orthopedic Surgery
Narihito Nagoshi Orthopedic Surgery
Katherine Palmieri Anesthesiology
Anoushka Singh Nursing
Eve Tsai Neurosurgery
Alexander Vaccaro Orthopedic Surgery
Albert Yee Orthopedic Surgery
Methodologists (non-voting members)
Andrea C. Skelly, PhD, MPH Epidemiologist, Systematic Review
Methodologist
Joseph R. Dettori, PhD, MPH Epidemiologist, Systematic Review
Methodologist
Non-voting Observers
Chris Ahuja Neurosurgery
Maria Alvarez AOSpine International
Nancy Holmes AOSpine North America
Chi Lam AOSpine North America
Kelly McCormick AOSpine North America
Anick Nater Neurosurgery
Aria Nouri Research
Table 3. A Summary of the Clinical Questions Addressed in the
Systematic Reviews on Degenerative Cervical Myelopathy (DCM).
The Natural History of DCM
 What is the natural history of DCM?
 Which are the risk factors for progression of DCM?
Comparative Effectiveness of Operative and Nonoperative Treatment for
DCM
 What is the evidence of the efficacy, effectiveness and safety of
nonoperative treatment in patients with DCM compared with
surgical intervention?
 Do the outcomes of nonoperative treatment vary according to
myelopathy severity?
 Are minor injuries associated with neurological deterioration
among patients with cervical myelopathy or asymptomatic cervical
cord compression treated nonoperatively?
Nonoperative Treatment for DCM
 What is the change in function, pain, and quality of life following
structured nonoperative treatment?
 Is there variability in the change in function, pain, and quality of life
following different types of nonoperative treatment?
 Are there differences in outcomes following nonoperative
treatment between certain subgroups (eg, baseline severity score,
duration of symptoms)?
 What are the negative outcomes and harms associated with
structured nonoperative treatment?
Surgical Treatment for DCM
 What are the expected functional, disability, and pain outcomes
following surgical intervention for DCM?
 Do these expected outcomes of surgical intervention depend on
preoperative disease severity or duration of symptoms?
 What are the complications associated with surgical intervention?
The Management of Nonmyelopathic Patients with Cervical Spinal Cord
Compression, Canal Stenosis and/or OPLL
 What are the frequency and timing of symptom development?
 What are the clinical, radiographic, and electrophysiological
predictors of symptom development?
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data analysis/synthesis methods, risk of bias assessment, and
evaluation of the overall quality (strength) of evidence. Elec-
tronic databases searched included PubMed, ClinicalTrials.-
gov, EMBASE, The Cochrane Library, and others deemed
relevant by the review team. Spectrum methodologists pre-
pared standardized evidence summaries and syntheses of the
current evidence and key results; they presented these findings
to the full GDG on several occasions to obtain input from
clinical experts and to convey the overall quality of the
evidence.
Previous systematic reviews on the topics were evaluated
using the AMSTAR (A Measurement Tool to Assess Systema-
tic Reviews) Checklist.14 This system scores a systematic
review out of 11 based on the following criteria: (1) was an a
priori design provided; (2) was there duplicate study selection
and data extraction; (3) was a comprehensive literature search
performed; (4) was the status of publication used as an inclu-
sion criteria; (5) was a list of studies (included and excluded)
provided; (6) were the characteristics of the included studies
provided; (7) was the scientific quality of the included studies
assessed and documented; (8) was the scientific quality of the
included studies appropriate for formulating conclusions; (9)
were the methods used to combine the findings of studies
appropriate; (10) was the likelihood of publication bias
assessed; and (11) were conflicts of interest included.
Grading of Evidence
The overall quality of evidence was determined using methods
outlined by the GRADE Working Group.9,10 Spectrum meth-
odologists, experienced in the application of GRADE, pre-
sented syntheses of the overall strength (quality) of evidence
for specific outcomes. Details are provided in the individual
systematic reviews. In general, the risk of bias, consistency,
directness, precision, and publication bias were assessed across
included studies for each critical or important outcome. The
initial quality (strength) of the overall body of evidence was
considered “High” for randomized controlled trials and “Low”
for observational studies in most instances. The body of evi-
dence may be downgraded 1 or 2 levels based on the following
criteria: (1) risk of bias (study limitations), (2) inconsistency of
results, (3) indirectness of evidence, (4) imprecision of the
effect estimates (eg, wide confidence intervals), or (5) failure
to provide an a priori statement of subgroup analyses.10 If there
are no downgrades, the body of evidence may be upgraded 1 or
2 levels based on the following criteria: (1) large magnitude of
effect, (2) dose-response gradient, or (3) if all plausible biases
would decrease the magnitude of an apparent effect. The final
overall quality (strength) of evidence expresses the confidence
that the effect estimate lies close to the true effect: high (high
confidence that the estimate reflects the true effect), moderate
(moderate confidence), low (low confidence), or very low
(very little confidence; the true effect is likely to be substan-
tially different from the estimated effect).
Table 4. A Summary of the Clinical Questions Addressed in the
Systematic Reviews on Acute Spinal Cord Injury (SCI).
Timing of Surgical Decompression for Acute SCI
 What is the efficacy and effectiveness of early decompression
(24 hours) compared with late decompression (>24 hours) or
conservative therapy based on clinically important change in
neurological status?
 Does timing of decompression influence other functional
outcomes or administrative outcomes?
 What is the safety profile of early decompression (24 hours)
compared with late decompression (>24 hours) or conservative
therapy?
 What is the evidence that early decompression (24 hours) has
differential efficacy or safety in subpopulations?
 What is the cost-effectiveness of the treatment options above?
The Use of Methylprednisolone Sodium Succinate (MPSS) in Acute SCI
 What is the efficacy and effectiveness of MPSS compared with no
pharmacologic treatment?
 What is the safety profile of MPSS compared with no
pharmacologic treatment?
 What is the evidence that MPSS has differential efficacy or safety
issues in subpopulations?
The Type and Timing of Anticoagulation in Acute SCI
 What is the effectiveness and safety of a pharmacological
anticoagulation strategy compared to no prophylaxis, placebo
or another pharmacological strategy for preventing deep
vein thrombosis (DVT) and pulmonary embolism (PE) after
acute SCI?
 What is the comparative effectiveness and safety of mechanical
prophylaxis strategies alone or in combination with other
prophylactic strategies for preventing DVT and PE after
acute SCI?
 What is the comparative effectiveness and safety of invasive
anticoagulation strategies alone or in combination with other
prophylactic strategies for preventing DVT and PE after acute SCI?
 What is the optimal timing to initiate and/or discontinue
pharmacological, mechanical and/or invasive anticoagulation
prophylaxis following acute SCI?
 What is the cost-effectiveness of the treatment options above?
The Role of Magnetic Resonance Imaging (MRI) in Acute SCI
 How does the acquisition of a baseline MRI influence management
strategy(ies) compared with no MRI (or other comparator), and
consequently, what changes does it effect in neurologic,
functional, patient-reported, and safety outcomes?
 Do spinal cord lesion characteristics, pattern and length identified
on baseline MRI predict neurologic, functional, patient-reported,
and safety outcomes?
 Do spinal cord characteristics identified on diffusion tensor
imaging (DTI) predict neurologic, functional, patient-reported,
and safety outcomes?
 Is there evidence to suggest that baseline MRI is cost-effective in
patients with acute SCI?
The Type and Timing of Rehabilitation in Acute SCI
 Does the time interval between injury and commencing
rehabilitation affect outcome?
 What is the comparative effectiveness of different rehabilitation
strategies, including different intensities and durations of
treatment?
 Are there patient or injury characteristics that impact the efficacy
of rehabilitation?
 What is the cost-effectiveness of various rehabilitation strategies?
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Recommendation and Guideline Development
A core group of individuals from the GDG constructed the key
questions to be addressed by these guidelines.
DCM Guidelines.
 Should operative management be used to treat patients
with severe DCM?
 Should operative management be used to treat patients
with moderate DCM?
 Should nonoperative management be used to treat
patients with mild DCM?
 Should operative management be used to treat patients
with mild DCM?
 Should operative management be used to treat nonmye-
lopathic patients with imaging evidence of cord com-
pression without signs or symptoms of radiculopathy?
 Should operative management be used to treat non-
myelopathic patients with imaging evidence of cord
compression and clinically/electrophysiologically
diagnosed radiculopathy?
SCI Guidelines.
Timing of surgery:
 Should we recommend early decompressive surgery (24
hours after injury) for adult patients with an incomplete
pattern of neurological injury consistent with central cord
syndrome, no radiological evidenceofmechanical instabil-
ity, and radiological evidence of spinal cord compression?
 Should we recommend early decompressive surgery
(24 hours after injury) for adult patients with acute
SCI regardless of neurological level of injury at hospital
admission?
The use of methylprednisolone sodium succinate (MPSS):
 Should a 24-hour infusion of high-dose MPSS be admi-
nistered to adult patients with acute SCI after 8 hours
after injury?
 Should a 24-hour infusion of high-dose MPSS be admi-
nistered to adult patients with acute SCI within 8 hours
of injury?
 Should a 48-hour infusion of high-dose MPSS be admi-
nistered to adult patients with acute SCI?
The type and timing of anticoagulation:
 Should prophylactic pharmacological strategies be
employed to minimize the risk of thromboembolic
events in the acute period after SCI?
 What prophylactic pharmacological strategy should
be employed to minimize the risk of thromboembolic
events in the acute period after traumatic SCI?
 Should prophylaxis be initiated within 72 hours (vs after
72 hours) of SCI?
 Should prophylactic pharmacologic strategies be used
alone or in combination with mechanical approaches?
The role of magnetic resonance imaging (MRI):
 Should baseline MRI be performed to facilitate clinical
management decisions in adult patients with acute
SCI?
 Should baseline MRI be performed in adult patients with
acute SCI to facilitate improved prognostication of neu-
rologic and functional outcomes?
The type and timing of rehabilitation:
 Should early (vs late) rehabilitation be recommended for
individuals with acute or subacute SCI?
 Should body weight supported treadmill training (vs
conventional rehabilitation) be recommended for
patients with acute or subacute SCI?
 Should functional electrical therapy (vs conventional
rehabilitation) be recommended for patients with acute
or subacute SCI?
 Should training unsupported sitting (vs control/standard
in-patient therapy) be recommended for patients with
acute or subacute SCI?
Input was obtained from other members of the GDG via a
series of teleconferences and incorporated into a guideline
development protocol, based on the COGS checklist.3,7 This
protocol included the general focus, purpose and rationale of
the guideline, relevant definitions, the aspects of care covered
by the guideline, users and settings, and implementation stra-
tegies. GDG members were required to review and provide
written approval of the protocol.
Recommendations were developed using the process out-
lined by the GRADE Guideline Development Tool (GDT,
Version 1) and the related “evidence-to-recommendation”
framework. The GDT process consists of examining and
weighing the evidence, formulating evidence-based recom-
mendations, assessing the overall certainty of evidence and
determining the strength of recommendation15-18 for each
clinical question. The framework provides a systematic pro-
cess to document the certainty of evidence, how stake-
holders value the main outcomes, the size of anticipated
desirable and undesirable effects (and the size of desirable
effects relative to undesirable effects), resource use/cost-
effectiveness, acceptability of options to key stakeholders,
impact on health inequities, and feasibility of implementa-
tion. It also facilitates formal discussion on the balance of
consequences and the type of recommendation. The frame-
work was used by members of the GDG Leadership Team
(Chairs, Vice Chair(s), and at least one general GDG mem-
ber) to draft “strawman” recommendations (Table 5).
Some of the questions included in the GDT required discus-
sion and interpretation. For the question on the overall certainty
of the evidence, the quality of evidence across all critical out-
comes, including desirable and undesirable effects, was con-
sidered as described in the GRADE Handbook.10 With respect
to the question on anticipated desirable effects, the importance
of desirable effects and the number of people affected were
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considered. Prior to drafting the “strawman” recommenda-
tions, the GDG leadership group identified and ranked out-
comes by their relative importance. Specific outcomes were
classified as (1) critically important in determining treat-
ment options and decision making, (2) important but not
critical for decision making, and (3) of limited importance.
Finally, for the question on health inequities, the GDG
group agreed to assume that the recommendation would
inform a change in policy.
Evidence from the systematic reviews was presented to the
full GDG at in-person and follow-up webinar meetings by
methodologists from Spectrum Research, Inc. The GDG dis-
cussed the available evidence, including important knowledge
gaps, and presented relevant perspectives based on their clin-
ical experiences. Perspectives from patients and advocates
were also considered; in the absence of representation from
these stakeholders, clinical experts were asked to provide the
patient perspective based on their experience. The “strawman”
recommendations facilitated initial discussion at in-person and
webinar meetings involving the full GDG. The GDT (Version
1) was used in real-time to refine and finalize recommenda-
tions, document key discussion points, and summarize voting
results. An audience response system was used for voting dur-
ing in-person meetings to ensure anonymity; only methodolo-
gists were aware of the voting patterns based on discipline. In
cases of voting discrepancies, the GDG discussed alternative
perspectives and refined the wording of the recommendation if
necessary.
Additional anonymous votes were completed electronically
using SurveyMonkey; one vice chair and one methodologist
were aware of these voting results. A modified Delphi process
was used to reach consensus; however, for some elements and
recommendations, there were varying perspectives and opi-
nions, and consensus was not achieved. Votes were recorded
and are presented in the “rationale for recommendation” sec-
tions when a consensus was not reached or when there was not
a large majority. In the absence of strong evidence, the GDG
was required to document their consideration of preferences
and values and the role of clinical expertise in formulating the
final recommendation.
Types and Interpretation of Recommendations
The 4 factors that influence the strength of a recommendation
are the balance between desirable and undesirable outcomes,
the confidence in the magnitude of the estimate of effect, the
confidence in values and preferences, and resource use.10 For
example, the larger the difference between the desirable and
undesirable consequences, the more likely a strong recommen-
dation is warranted. In contrast, the smaller the net benefit of an
option, and the lower the certainty for that benefit, the more
likely a weak recommendation is warranted. Furthermore, the
higher the quality of evidence, the more likely a strong recom-
mendation is justified, and the greater the variability or uncer-
tainty in values and preferences, the more likely a weak
Table 5. GRADE Guideline Development Evidence to
Recommendation Framework: Questions and Response Options.
Question Response Options
Benefits and Harms
What is the overall certainty of
the evidence?
No included studies, very low,
low, moderate, high
Is there important uncertainty
about how much people value
the main outcomes?
Important uncertainty or
variability, possibly important
uncertainty or variability,
probably no important
uncertainty or variability, no
important uncertainty or
variability, no known
undesirable
Are the desirable anticipated
effects large?
No, probably no, uncertain,
probably yes, yes, varies
Are the undesirable anticipated
effects small?
No, probably no, uncertain,
probably yes, yes, varies
Are the desirable effects large
relative to the undesirable
effects?
No, probably no, uncertain,
probably yes, yes, varies
Resource Use
Are the resources required small? No, probably no, uncertain,
probably yes, yes, varies
Is the incremental cost small
relative to the net benefits?
No, probably no, uncertain,
probably yes, yes, varies
Equity
What would be the impact on
health inequities?
Increased, probably increased,
uncertain, probably reduced,
reduced, varies
Acceptability
Is the option acceptable to key
stakeholders?
No, probably no, uncertain,
probably yes, yes, varies
Feasibility
Is the option feasible to
implement
No, probably no, uncertain,
probably yes, yes, varies
Forming the Recommendation
Balance of consequences Undesirable consequences clearly
outweigh desirable
consequences in most settings
Undesirable consequences
probably outweigh desirable
consequences in most
settings
The balance between desirable
and undesirable consequences
is closely balanced or
uncertain
Desirable consequences probably
outweigh undesirable
consequences in most settings
Desirable consequences clearly
outweigh undesirable
consequences in most settings
Type of recommendation We recommend against offering
this option
We suggest not offering this
option
We suggest offering this option
We recommend offering this
option
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recommendation is warranted. Finally, in terms of resource use,
the higher the cost of an intervention, the less likely a strong
recommendation is justified.
The wording of the recommendation indicates whether it
is “strong” or “weak;” the word “suggest” indicates a
weaker recommendation, whereas the word “recommend”
indicates a stronger statement.10 For a strong recommenda-
tion, (1) most patients would want the recommended course
of action and only a small proportion would not; (2) the
recommendation would apply to most individuals; formal
decision aids are not likely to be needed to help individuals
make decisions consistent with their values and preferences;
and (3) the recommendation can be adopted as a policy in
most situations. In contrast, for a weak recommendation, (1)
the majority of patients would want the recommended
course of action, but many would not; (2) clinicians should
support each patient in reaching a management decision
consistent with his or her values and preferences; decision
aids may support individuals in reaching such decisions; and
(3) policymaking will require substantial debate and invol-
vement of stakeholders.
In general, GRADE discourages guideline panels from
making strong recommendations when their confidence in
estimates of effect for critical outcomes is low or very
low. GRADE has identified 5 paradigmatic situations in
which strong recommendations may be warranted despite
low or very low quality of evidence. These include the
following:
 When low-quality evidence suggests benefit in a life-
threatening situation (evidence regarding harms can be
low or high)
 When low-quality evidence suggests benefit and high-
quality evidence suggests harm or a very high cost
 When low-quality evidence suggests equivalence of 2
alternatives, but high-quality evidence suggests less
harm for one of the competing alternatives
 When high-quality evidence suggests equivalence of 2
alternatives and low-quality evidence suggests harm in
one alternative
 When high-quality evidence suggests modest benefits
and low/very low quality of evidence suggests possibil-
ity of catastrophic harm
Internal Appraisal
A draft of the full guideline was distributed to GDG mem-
bers for feedback and approval using electronic voting.
GDG leadership reviewed these comments and incorporated
them in a revised guideline prior to external review.
Substantive changes were subject to re-vote of the GDG.
GDG Vice-Chairs independently appraised the final guide-
line using Appraisal of Guidelines for Research & Evalua-
tion II (AGREE II) criteria19 to assess the validity of the
guideline and the development process and to determine
major areas of deficiency. Results were reviewed within the
GDG leadership and any necessary corrections were made.
Areas requiring substantive changes were presented to the
full GDG and subject to re-vote.
External Review
A multidisciplinary group of clinicians and patient advo-
cates were invited by the leadership group to externally
review the guideline document. These individuals were
selected based on their clinical expertise in a specific area
and their willingness to participate. Comments and feedback
were assessed by the GDG leadership and methodologists
and incorporated into the final draft. Invited external
reviewers included a broad spectrum of potential stake-
holders (primary care physicians, neurosurgeons, orthopedic
surgeons, critical care physicians, vascular medicine spe-
cialists, rheumatologists, and neurologists) and were asked
to disclose financial and intellectual conflicts of interest.
The Joint Guideline Committee at the AANS/CNS also
externally reviewed all documents contributing to these
guidelines. Reviewer comments were summarized by the
GDG leadership and methodologists and made available to
the full GDG together with the revised guideline. Substan-
tial changes were subjected to re-vote by the full GDG and
are reflected in the final guideline. The final guideline doc-
uments were distributed to AOSNA, AOSpine International,
and CSRS for their approval.
Update Planning
The guidelines will be reviewed by the primary sponsor at
3 years to a maximum of 5 years following publication. A
working group, consisting of a chair, a vice chair, an
independent methodologist, and 2 to 5 content experts will
follow a structured process to review the body of literature
and search for new evidence that may influence the pro-
posed recommendations. The working group will discuss
the need to update the guideline with the leadership of the
sponsoring organization. An update will be considered if
there are changes in (1) the evidence related to harms and
benefits, (2) outcomes which would be considered impor-
tant for decision making, (3) ranking of current critical
and important outcomes, and (4) available interventions
and resources.20
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GDG Member Employment (Specialty) Industrial/Institutional Disclosures Intellectual Disclosures
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Trauma)
 None  None
Paul Arnold Surgeon (Neurosurgery,
spine)
 None  None
Darrel Brodke Surgeon (Orthopaedic—
Spine)
 None  Prescribe, treat, recommend—treats
patients with CSM
Anthony Burns Physical Medicine/Rehab
(Spinal Cord Medicine)
 None  Prescribe, recommend, treat—prescribes
therapies/interventions for individuals with
myelopathies
Simon Carette Rheumatologist  None  None
Robert Chen Neurologist (Neurology
and Neurophysiology)
 None  Prescribe, recommend, treat—prescribes/
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Kazuhiro
Chiba
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management of CSM
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James Harrop Surgeon (Neurosurgery,
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 Board membership—AOSpine: $0
 Consultancy—DePuy spine: $30K
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no concrete beliefs
 Prescribe, recommend, treat—generally
prescribes treatments for CSM
Langston Holly Surgeon (Spine)  Patent with Medtronic that may result in
future income
 Expert witness/testimony: $12K paid to
institution
 NIH grant: $330K paid to institution
 None
Sukhvinder
Kalsi-Ryan
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Clinician Scientist
 Consultancy—Neural Outcomes
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 Officership—CSO of own company—
Neural Outcomes: $NR
 Grants/contracts—CIHR, CINF, RHI, ONF:
$NR
 Royalties—GRASSP version 1.0: $NR
 Authorship—first and coauthor on many
CSM publications
Mark Kotter Surgeon (Spinal
Neurosurgery)
 None  Authorship—research papers on CSM,
mainly investigating the underlying
pathological changes and mechanisms of
regeneration
 Prescribe, recommend, treat—as clinician,
cares for CSM patients, and observes that
there are no accepted guidelines on the
subject thus far, and thus uncertainty as to
how patients should be managed
Brian Kwon Surgeon (Spine)  None  Public opinion—participated in debate on
laminectomy & fusion versus laminoplasty at
the AAOS meeting
 Prescribe, recommend, treat—treats
condition nonoperatively and surgically
Ralph Marino Physical Medicine/
Rehabilitation (Spinal
Cord Injury)
 None  Prescribe, recommend, treat—prescribes
rehabilitation services for persons with
cervical myelopathy
Allan Martin Surgeon (Neurosurgery)  None  None
James
Middleton
Rehabilitation Medicine  None  None
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James Milligan Family Medicine (Mobility
issues, SCI)
 None  None
Narihito
Nagoshi
Surgeon (Spine)  None  None
Hiroaki
Nakashima
Surgeon (Spine)  None  Authorship—much research regarding CSM
 Prescribe, recommend, treat—would
recommend treatment
John Rhee Surgeon (Orthopaedic)  Board membership—CSRS: $0
 Consultancy—Biomet spine: $5K
 Royalties—Biomet spine: $45K
 Stock ownership: Phygen/Alphatec
 Payment for lectures—Zimmer spine: $20K,
Depuy Spine: $10K
 Authorship—research papers on CSM, no
strongly held beliefs
 Prescribe, recommend, treat—as a surgeon,
prescribes/recommends treatments for
CSM
Daniel Riew Surgeon (Cervical Spine)  Chairman of Board—AOSpine International:
<$50K
 Royalties—Biomet, Medtronic: <$1M
 Payment for lectures—AOSpine, NASS:
<$20K
 Stock options: Expanding Orthpedics,
Amedica, Benvenue, Nexgen, Spine, Osprey,
Paradigm, Spinal Kinetics, Spineology,
Vertiflex, PSD: <$25K
 Travel accommodations/meeting
expenses—AOSpine NASS, SRS,
Broadwater: <150K
 Grants—AOSpine, cerapedics, Medtronic:
$50K
 Authorship—many publications in area of
expertise
Anoushka
Singh
Nurse, Researcher
(Neurospine)
 None  Authorship—work on CSM as part of PhD
and postdoctoral work
Sumeet Sodhi Primary Care Physician  None  Prescribe, treat, recommend—as a family
doctor, does prescribe/recommend CSM
Lindsay
Tetreault
Other  Grant—potential future AOSpine Strategic
Grant
 Authorship—Predicting Outcome in CSM
Jeff Wang Surgeon (Spine)  Board membership—AOSpine: $86597
 Honorariums—CSRS: $0; NASS: $0; CSRF:
$0
 Editorial boards: Spine, JAAOS, The Spine
Journal, Journal of Spinal Disorders and
Techniques, Global Spine Journal, The Journal of
Orthopaedic Trauma
 Royalties—Stryker: $423, Osprey: $725,
Biomet: $602290, Synthes: $12105,
Seaspine: $33823, Amedica: $28 491,
Aesculap: $3813
 Stock Options—no money paid, but
personal investments in: Bone Biologics,
Alphatech, Axiomed, Amedica, Corespine,
Expanding Ortho, Pioneer, Axis, Syndicom,
VG Innovations, Pearldiver, Flexuspine,
Fziomed, Benvenue, Promethean, Nexgen,
Electrocore, Surgitech
 Expert witness—yes
 Travel reimbursements—AOSpine, CSRS,
NASS, CSRF
 Fellowship funding paid to institution—USC
Department of Orthopaedic Surgery: AO
Foundation $75K
 Public opinion—has presented talks and
moderated educational sessions at meetings
on this topic
 Organization with stated opinion—member
of NASS that has an AUC on cervical
surgery, involved in formulating/voting for
NASS
 Prescribe, recommend, treat—operates on
patients with cervical pathology
Jefferson
Wilson
Surgeon (Neurosurgery,
Spine)
 None  Authorship—several CSM manuscripts
 Prescribe, recommend, treat—recommends
surgery for CSM
Albert Yee Surgeon (Spine)  None  Prescribe, recommend, treat—involved in
spine case
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Table A2. Members of the SCI Guideline Development Group: Conflict of Interests.
GDG Member Employment (Specialty) Industrial/Institutional Disclosures Intellectual Disclosures
Bizhan Aarabi Surgeon (Neurosurgery,
Trauma)
 None  None
Paul Arnold Surgeon (Neurosurgery,
Spine)
 None  None
Darrel Brodke Surgeon (Orthopaedic—
Spine)
 None  Prescribe, treat, recommend—treats
patients with CSM
Anthony
Burns
Physical Medicine/Rehab
(Spinal Cord Medicine)
 None  Prescribe, recommend, treat—prescribes
therapies/interventions for individuals with
myelopathies
Simon Carette Rheumatologist  None  None
Robert Chen Neurologist (Neurology
and Neurophysiology)
 None  Prescribe, recommend, treat—prescribes/
recommends CSM
Kazuhiro
Chiba
Surgeon (Spine and Spinal
Cord Surgery)
 None  Authorship—Japanese guideline for the
management of CSM
Michael
Fehlings
Surgeon (Neurosurgery)  None  Authorship—has published original research
in CSM
 Prescribe, recommend, treat—is an active,
practicing clinician in the field
Julio Furlan Neurologist  None  Prescribe, recommend, treat—assesses and
manages patients with CSM
James Harrop Surgeon (Neurosurgery,
Spine)
 Board membership—AOSpine: $0
 Consultancy—DePuy spine: $30K
 Expert advisor—Tejin, Bioventus, Asterins:
$20K
 Authorship—written several papers on CSM
on general care and several studies, has no
concrete beliefs
 Prescribe, recommend, treat—generally
prescribes treatments for CSM
Langston
Holly
Surgeon (Spine)  Patent with Medtronic that may result in
future income
 Expert witness/testimony: $12K paid to
institution
 NIH grant: $330K paid to institution
 None
Sukhvinder
Kalsi-Ryan
Physical Therapist,
Clinician Scientist
 Consultancy—Neural Outcomes
Consulting, Inc: $NR
 Officership—CSO of own company—
Neural Outcomes: $NR
 Grants/contracts—CIHR, CINF, RHI, ONF:
$NR
 Royalties—GRASSP version 1.0: $NR
 Authorship—first and co-author on many
CSM publications
Mark Kotter Surgeon (Spinal
Neurosurgery)
 None  Authorship—research papers on CSM,
mainly investigating the underlying
pathological changes and mechanisms of
regeneration
 Prescribe, recommend, treat—as clinician,
cares for CSM patients, and observes that
there are no accepted guidelines on the
subject thus far, and thus uncertainty as to
how patients should be managed
Brian Kwon Surgeon (Spine)  None  Public opinion—participated in debate on
laminectomy and fusion versus laminoplasty
at the AAOS meeting
 Prescribe, recommend, treat—treats
condition non-operatively and surgically
Ralph Marino Physical Medicine/
Rehabilitation (Spinal
Cord Injury)
 None  Prescribe, recommend, treat—prescribes
rehabilitation services for persons with
cervical myelopathy
Allan Martin Surgeon (Neurosurgery)  None  None
James
Middleton
Rehabilitation Medicine  None  None
James Milligan Family Medicine (Mobility
issues, SCI)
 None  None
Narihito
Nagoshi
Surgeon (Spine)  None  None
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GDG Member Employment (Specialty) Industrial/Institutional Disclosures Intellectual Disclosures
Hiroaki
Nakashima
Surgeon (Spine)  None  Authorship—much research regarding CSM
 Prescribe, recommend, treat—would
recommend treatment
John Rhee Surgeon (Orthopaedic)  Board membership—CSRS: $0
 Consultancy—Biomet Spine: $5K
 Royalties—Biomet Spine: $45K
 Stock ownership: Phygen/Alphatec
 Payment for lectures—Zimmer spine: $20K,
Depuy Spine: $10K
 Authorship—research papers on CSM, no
strongly held beliefs
 Prescribe, recommend, treat—as a surgeon,
prescribes/recommends treatments for CSM
Daniel Riew Surgeon (Cervical Spine)  Chairman of Board—AOSpine International:
<$50K
 Royalties—Biomet, Medtronic: <$1M
 Payment for lectures—AOSpine, NASS:
<$20K
 Stock options: Expanding Orthpedics,
Amedica, Benvenue, Nexgen, Spine, Osprey,
Paradigm, Spinal Kinetics, Spineology,
Vertiflex, PSD: <$25K
 Travel accommodations/meeting
expenses—AOSpine NASS, SRS,
Broadwater: <150K
 Grants—AOSpine, cerapedics,Medtronic: $50K
 Authorship—many publications in area of
expertise
Anoushka
Singh
Nurse, Researcher
(Neurospine)
 None  Authorship—work on CSM as part of PhD
and postdoctoral work
Sumeet Sodhi Primary Care Physician  None  Prescribe, treat, recommend—as a family
doctor, does prescribe/recommend CSM
Lindsay
Tetreault
Other  Grant—potential future AOSpine Strategic
Grant
 Authorship—Predicting Outcome in CSM
Jeff Wang Surgeon (Spine)  Board membership—AOSpine: $86,597
 Honorariums—CSRS: $0; NASS: $0; CSRF:
$0
 Editorial boards: Spine, JAAOS, The Spine
Journal, Journal of Spinal Disorders and
Techniques, Global Spine Journal, The Journal of
Orthopaedic Trauma
 Royalties—Stryker: $423, Osprey: $725,
Biomet: $602290, Synthes: $12105,
Seaspine: $33823, Amedica: $28 491,
Aesculap: $3813
 Stock options—no money paid, but personal
investments in: Bone Biologics, Alphatech,
Axiomed, Amedica, Corespine, Expanding
Ortho, Pioneer, Axis, Syndicom, VG
Innovations, Pearldiver, Flexuspine, Fziomed,
Benvenue, Promethean, Nexgen,
Electrocore, Surgitech
 Expert witness—yes
 Travel reimbursements—AOSpine, CSRS,
NASS, CSRF
 Fellowship funding paid to institution— USC
Department of Orthopaedic Surgery: AO
Foundation $75K
 Public opinion—has presented talks and
moderated educational sessions at meetings
on this topic
 Organization with stated opinion—member
of NASS that has an AUC on cervical
surgery, involved in formulating/voting for
NASS
 Prescribe, recommend, treat—operates on
patients with cervical pathology
Jefferson
Wilson
Surgeon (Neurosurgery,
Spine)
 None  Authorship—several CSM manuscripts
 Prescribe, recommend, treat—recommends
surgery for CSM
Albert Yee Surgeon (Spine)  None  Prescribe, recommend, treat—involved in
spine case
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